Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Joly, V.; Moroni, M.; Concia, Ercole; Lazzarin, A.; Hirschel, Bernard; Jost, J.; Chiodo, F.; Bentwich, Z.; Love, W. C.; Hawkins, D. A.; Wilkins, E. G.; Gatell, A. J.; Vetter, N.; Greenwald, C.; Freimuth, W. W.; de Cian, W.

Scientific article

English

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

ContributorsJoly, V.; Moroni, M.; Concia, Ercole; Lazzarin, A.; Hirschel, Bernard; Jost, J.; Chiodo, F.; Bentwich, Z.; Love, W. C.; Hawkins, D. A.; Wilkins, E. G.; Gatell, A. J.; Vetter, N.; Greenwald, C.; Freimuth, W. W.; de Cian, W.

Published inAntimicrobial agents and chemotherapy, vol. 44, no. 11, p. 3155-3157

Publication date2000

Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Keywords

Anti-HIV Agents/ therapeutic use
Delavirdine/ therapeutic use
Double-Blind Method
Drug Resistance, Microbial
Drug Therapy, Combination
HIV Infections/ drug therapy
HIV Reverse Transcriptase/genetics
HIV-1/drug effects/genetics
Humans
Treatment Outcome
Zidovudine/therapeutic use

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Citation (ISO format)

JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial agents and chemotherapy, 2000, vol. 44, n° 11, p. 3155–3157.

Article

Identifiers

PID : unige:7355
PMID : 11036040

Additional URL for this publicationhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC101620/pdf/ac003155.pdf

Journal ISSN0066-4804

513views

0downloads

Creation21/06/2010 10:24:57

First validation21/06/2010 10:24:57

Update time14/03/2023 15:44:18

Status update14/03/2023 15:44:17

Last indexation29/10/2024 15:13:14

Archive ouverte UNIGE

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Technical informations